EUVIMEDEUVIMED entdecken
Scoping ReviewÜbersichtsarbeitOpen Access · CC BY 4.0

Evaluating Early‐Stage Oncology Clinical Trial Designs in the Era of Project Optimus: A Scoping Review

Marie-Karelle Riviere iD, Anaïs Andrillon iD, Pavel Mozgunov, Emma Gerard iD, Moreno Ursino iD

Pharmaceutical Statistics · 2026-11 · 25 (6)

DOI: 10.1002/pst.70131 ↗

Kurz gefasst

Scoping Review in der Zeitschrift Pharmaceutical Statistics, online erschienen am 05.11.2026. Verfasst von Marie-Karelle Riviere und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Statistical Methodology, SARYGA, Tournus, France. Hauptthemen laut MEDLINE: Research Design, Neoplasms, Clinical Trials as Topic, Antineoplastic Agents. Die Arbeit nennt 190 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In 2021, the FDA initiated Project Optimus to reform dose optimization and selection in early‐phase oncology, highlighting that doses and schedules of new therapies are often inadequately characterized and that traditional dose‐finding approaches should be revised. The project also encourages early and comprehensive exploration of multiple doses during clinical development and advocates for a more patient‐centered approach incorporating not only toxicity but also the individual's response, biomarkers, pharmacokinetics/pharmacodynamics, or patient‐reported outcomes to inform dosage decisions. We conducted a scoping review of the statistical and methodological literature on early‐phase oncology trial designs in light of Project Optimus. The review aims to determine which key elements of the Optimus guidelines are incorporated into existing early‐phase trial design methodologies and to assess remaining methodological gaps. It also aims to address the following question: What progress has been achieved so far, and what improvements can be made in light of the directives from Project Optimus? The review was organized according to the PRISMA‐ScR guidelines. A total of 160 journals were finally retained, with 722 papers considered for the scoping review, published between January 1990 and September 2025. The database containing the reviewed papers is made available to the reader.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Research DesignNeoplasmsClinical Trials as TopicAntineoplastic AgentsMedical OncologyHumansDose-Response Relationship, Drug

Stichwörter der Autor:innen

adaptive designdose optimizationdose‐findingdrug developmentmaximum tolerated doseoptimal dose

Substanzen

Antineoplastic Agents

Autor:innen und Institutionen

  • Department of Statistical Methodology, SARYGA, Tournus, France.
  • INSERM, Inria, Université Paris Cité, UMR 1346, HeKA, Paris, France.
  • ECSTRRA Team, INSERM U1342 IRSL, Université Paris Cité, Paris, France.
  • MRC Biostatistics Unit, University of Cambridge, Cambridge, UK.
  • Evidence Generation and Decision Sciences, SANOFI, Gentilly, France.

ORCID-Profile: Marie-Karelle Riviere, Anaïs Andrillon, Emma Gerard, Moreno Ursino

Zitieren

APA

Riviere, M. K., Andrillon, A., Mozgunov, P., Gerard, E., & Ursino, M. (2026). Evaluating Early‐Stage Oncology Clinical Trial Designs in the Era of Project Optimus: A Scoping Review. Pharmaceutical Statistics, 25(6). https://doi.org/10.1002/pst.70131

Vancouver

Riviere MK, Andrillon A, Mozgunov P, Gerard E, Ursino M. Evaluating Early‐Stage Oncology Clinical Trial Designs in the Era of Project Optimus: A Scoping Review. Pharmaceutical Statistics. 2026;25(6). doi:10.1002/pst.70131

BibTeX
@article{Riviere2026,
  author = {Riviere, Marie-Karelle and Andrillon, Anaïs and Mozgunov, Pavel and Gerard, Emma and Ursino, Moreno},
  title = {Evaluating Early‐Stage Oncology Clinical Trial Designs in the Era of Project Optimus: A Scoping Review},
  journal = {Pharmaceutical Statistics},
  year = {2026},
  volume = {25},
  number = {6},
  doi = {10.1002/pst.70131}
}
Kostenlos starten →